Sign In
NewsRadar

Bioxell S.p.A.

BioXell is a private biopharmaceutical company focusing on the discovery and development of new treatments for urological and inflammatory disorders that represent large, currently underserved markets. The Company's goal is to become a market leader in urology by maximizing the commercial potential of its lead compound, BXL628, building a leading urology franchise, and leveraging existing platforms into profitable collaborations.

• Show past press releases
• Edit this company

Elevator Pitch
With analogues based on its proprietary Vit D3 technology platform, BioXell has three Phase II clinical programmes underway, specifically evaluating BXL628 for Benign Prostatic Hyperplasia, Overactive Bladder, and Non-Bacterial Chronic Prostatitis. The Company has a partnership with Merck to advance its TREM receptor biology programme into the clinic. In addition, BioXell recently in-licensed MNAC13, a novel anti-TrkA monoclonal antibody for the treatment of pain, from Lay Line Genomics.

Contact Information
Address:
 
 
Phone:
Fax:
Web:
Contact:
 
 
Via Olgettina 58
Milano  20132
Italy
+39 (0)2 210 49 520
+39 (0)2 210 49 529
http://www.bioxell.com
Angela Evans
+39 (0)2 210 49 520

Company Facts
Founded:Jan 2002
Founders:Michael Steinmetz, Francesco Sinigaglia, Luciano Adorini
CEO:Francesco Sinigaglia
CTO or technical lead:Luciano Adorini
CFO or finance director:Alex Martin
Head of Sales:
Head of Marketing:

Stage:Growth
Category:Biotechnology & Healthcare
Sector:Biopharmaceuticals
Employees:63
Profitability:Pre-revenue
Funding raised:Yes
Funding sought:Yes
Seeking Partnerships:Yes

Non-executive Board Members

  • Michael Steinmetz, General Partner, MPM Capital, Boston, USA
  • Bernd Seizinger, CEO, GP C Biotech, Munich, Germany
  • Francesco De Rubertis, Partner, Index Ventures, Geneva, Switzerland
  • Joachim Rothe, Partner , LSP, Amsterdam, The Netherlands
  • Thomas Szucs, Chairman, BB BIOTECH, Switzerland
  • Harrold van Barlingen, General Partner, AlpInvest Partners, Amsterdam
  • Peter van Brummelen, Consultant, Van Brummelen Global Drug Development Consultancy
  • Hubert Birner, General Partner, TVM Capital

    Key Customers

    Key Business Partners

  • Hoffmann La-Roche Ltd
  • Merck & Co.
  • Lay Line Genomics
  • ProStrakan

    Key Competitors

    Capital Raised
    DateSizeInvestors
    To view this information you must be signed in and subscribed to the online dataservice, sign in here.

    To read more about the Online data service click here

    Public Offerings
    DateTypeExchange
    No public offerings


  • Data


    26,261
    Tech investments
    From our Online Data Service
    16,961
    VC-backed companies
    From our Radar


    Recent Deals


    DATEAMOUNTSECTOR
    Oct 19€3.0MInternet services
    Oct 19€6.0MBusiness applications
    Oct 18€11.0MConsumer electronics
    Oct 18€5.0MBusiness applications
    Oct 18€2.3MInternet services
    Oct 17€5.9MBiopharmaceuticals
    Oct 16€51.0MArtificial Intelligence

    For information on Europe's most extensive database on technology funding click here!

    Events



    Press Releases


    May 28
    Identiq
    identiq raises $5m seed, launches privacy-first identity validation...

    Apr 29
    Nethone
    nethone raised over $1 million from innovation nest

    Oct 1
    The Link App
    the link app launches version 2.0

    Mar 29
    Addex Therapeutics
    addex sucessfully raises chf40 million in capital increase

    Jan 2
    Urban Jungle
    urban jungle raises 1m in seed funding to build tech-enabled home ...





    About usContact usLegal Information
    Copyright 1999-2019
    Emerging Technology Research Europe Inc. All rights reserved.